Market Re-Cap: What Happened Last Week (For 27th Jan week) US Market US markets faced disruptions caused by low-cost Chinese AI startup DeepSeek, with$E-mini S&P 500 Futures(MAR5) (ESmain.US)$and$E-mini NASDAQ 100 Futures(MAR5) (NQmain.US)$falling 1.41% and 2.98% respectively on Monday. However, a late-week recovery saw tech stocks rebounding, lifting the S&P 500 by 0.34% and the NASDAQ by 1.56%. The$USD (USDindex.FX)$strengthened following the White...
Recent insider selling at Fortive suggests shares may be overpriced. Despite profitability and growth, the history of share sales is concerning. High insider ownership aligns management with shareholders, but lack of insider buying is worrisome.
Fortive's high P/E ratio is justified by its superior earnings outlook. Shareholders' confidence in future earnings and the company's strong growth outlook make a significant share price drop unlikely.
CEO James A. Lico is confident in the company's 2024 outlook, citing a history of mid-single-digit core growth and mid-teens compounded earnings and free cash flow annually since 2019. He also emphasized the company's successful strategy and its impact over time.
Fortive's CEO views the acquisition as a significant stepping-stone for their Precision Technologies segment, hopeful of the synergies it'll bring to customer solutions and financial results. Foresees EA's addition to assist in the growing multi-industry market.
Fortive's projected growth could be factored into its current share price, possibly making it overvalued. Despite promising future growth, current pricing may not provide the best entry point for investors. Analysts suggest limited upside due to pricing alignment, with further exploration advised should prices decrease in light of growth prospects.
Gainers -$Luna Innovations (LUNA.US)$+8.55% (acquires LIOS Sensing from NKT A/S' NKT Photonics for 20 million in cash; divested Luna Labs for $21 mln) -$Clene (CLNN.US)$+3.5% (Presents Updated Clinical Data from Phase 2 RESCUE-ALS and REPAIR trials and Preclinical ALS data at 2022 MDA Clinical & Scientific Conference) -$AstraZeneca (AZN.US)$+2.3% ( AstraZeneca and$Merck & Co (MRK.US)$'s Lynparza (olaparib) has been approved in the ...
16
1
Report
No comment yet
- No more -
Sign in to post a comment
Trending Stocks
Top Gaining Chinese Stocks Top Gaining Chinese Stocks
102205868 (Tay) : Seem like going back 115 in pre market.
Cui Nyonya Kueh : Latest update: China retaliates.
Cui Nyonya Kueh :![](https://emoticon.futunn.com/rich_daily_life/O_02.png)